Rockwell Medical Inc   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: WIxom MI United States (1995)

Organization Overview

First Clinical Trial
2007
NCT00548249
First Marketed Drug
2003
calcitriol (rocaltrol)
First NDA Approval
2015
ferric pyrophosphate citrate (Triferic)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ROCKWELL MEDCL | Rockwell Medical | Rockwell Medical, Inc | ROCKWELL MEDICAL INC | Rockwell Medical Technologies | Rockwell Medical Technologies, Inc.

Active Ingredients

Marketed Drugs (2)

calcitriol (rocaltrol) (2003)

ferric pyrophosphate citrate (Triferic) (2015 NDA)

Drugs in Phase 4 Trials (1)

ferric pyrophosphate citrate (Triferic) (20 trials)

Drugs in Phase 3 Trials (1)

sodium bicarbonate (3 trials)

Drugs in Phase 2 Trials (5)

citric acid (2 trials)

ferric sulfate (2 trials)

heparin (liquaemin) (1 trial)

iron (1 trial)

sodium citrate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Iron-Deficiency (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 7